Ask a Question
  • Women's Health
  • Oncology
  • Cardio Renal
  • Ophthalmology

Medical Literature Recent Updates

Enzalutamide plus radium-223 in metastatic castration-res...
Survival Outcomes for Men with mCRPC with and without HRD...
Survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous re...
Decrease in Fracture Rate with Mandatory Bone-protecting ...
Alpha Emitter Radium-223 and Survival in Metastatic Prost...

ARASENS Publications

ARASENS Volume & Risk Subgroups Analysis
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disea...
ARASENS PSA Response Sub-Analysis
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, ...

ARAMIS Publications

View more
ARAMIS Primary Analysis
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
ARAMIS Final Analysis
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by...
ARAMIS Final Analysis
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by...
ARAMIS PSADT Subgroup Analysis
Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by...

Radium-223 Real World Studies

View more
Alpha Emitter Radium-223 and Survival in Metastatic Prost...
Safety and Survival of 177Lu-PSMA Therapy in Metastatic C...
Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castrati...
Clinical outcomes and treatment patterns in REASSURE: pla...
Radium-223 in combination with therapies for metastatic c...
Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an internation...

Canadian Radium-223 Real World Studies

Survival Outcomes for Men with mCRPC with and without HRD...
Survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous re...

ARANOTE Publications

ARANOTE Primary Publication
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate ...

Canadian Guidelines

Metastatic Castration-Naïve and Castration-Sensitive Pros...

PEACE-3 Publications

Enzalutamide plus radium-223 in metastatic castration-res...
Decrease in Fracture Rate with Mandatory Bone-protecting ...

ALSYMPCA Publications

Alpha Emitter Radium-223 and Survival in Metastatic Prost...